Azfar M, Gao W, Van den Haute C, Xiao L, Karsa M, Pandher R
Mol Oncol. 2025; 19(3):913-936.
PMID: 39981745
PMC: 11887671.
DOI: 10.1002/1878-0261.13789.
Wang W, Du Y, Datta S, Fowler J, Sang H, Albadari N
Genes Dis. 2025; 12(2):101156.
PMID: 39802403
PMC: 11719324.
DOI: 10.1016/j.gendis.2023.101156.
Soni N, Ora M, Bathla G, Desai A, Gupta V, Agarwal A
AJNR Am J Neuroradiol. 2024; 45(11):1624-1634.
PMID: 38844368
PMC: 11543070.
DOI: 10.3174/ajnr.A8237.
Miranda A, Pattnaik S, Hamilton P, Fuss M, Kalaria S, Laumont C
Sci Adv. 2024; 10(20):eadj5428.
PMID: 38748789
PMC: 11095474.
DOI: 10.1126/sciadv.adj5428.
dAmati A, Bargiacchi L, Rossi S, Carai A, Bertero L, Barresi V
Front Mol Neurosci. 2024; 17:1268038.
PMID: 38544524
PMC: 10966132.
DOI: 10.3389/fnmol.2024.1268038.
AF1q is a universal marker of neuroblastoma that sustains N-Myc expression and drives tumorigenesis.
Oskouian B, Lee J, Asgharzadeh S, Khan R, Zhang M, Weisbrod J
Oncogene. 2024; 43(16):1203-1213.
PMID: 38413795
PMC: 11014797.
DOI: 10.1038/s41388-024-02980-y.
The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer.
Ji Y, Zhang W, Shen K, Su R, Liu X, Ma Z
Nat Commun. 2023; 14(1):7794.
PMID: 38016952
PMC: 10684895.
DOI: 10.1038/s41467-023-43676-3.
Inhibition of Aurora-A/N-Myc Protein-Protein Interaction Using Peptidomimetics: Understanding the Role of Peptide Cyclization.
Dawber R, Gimenez D, Batchelor M, Miles J, Wright M, Bayliss R
Chembiochem. 2023; 25(2):e202300649.
PMID: 37907395
PMC: 10962542.
DOI: 10.1002/cbic.202300649.
Computational completion of the Aurora interaction region of N-Myc in the Aurora a kinase complex.
Altiner P, Cinaroglu S, Timucin A, Timucin E
Sci Rep. 2023; 13(1):18399.
PMID: 37884585
PMC: 10603048.
DOI: 10.1038/s41598-023-45272-3.
Repurposing disulfiram, an alcohol-abuse drug, in neuroblastoma causes KAT2A downregulation and in vivo activity with a water/oil emulsion.
Beaudry A, Jacques-Ricard S, Darracq A, Sgarioto N, Garcia A, Rode Garcia T
Sci Rep. 2023; 13(1):16443.
PMID: 37777587
PMC: 10543387.
DOI: 10.1038/s41598-023-43219-2.
Fused Imidazopyrazine-Based Tubulin Polymerization Inhibitors Inhibit Neuroblastoma Cell Function.
Thammathong J, Chisam K, Tessmer G, Womack C, Sidrak M, Weissmiller A
ACS Med Chem Lett. 2023; 14(9):1284-1294.
PMID: 37736192
PMC: 10510670.
DOI: 10.1021/acsmedchemlett.3c00298.
WDR5 facilitates recruitment of N-MYC to conserved WDR5 gene targets in neuroblastoma cell lines.
Bumpous L, Moe K, Wang J, Carver L, Williams A, Romer A
Oncogenesis. 2023; 12(1):32.
PMID: 37336886
PMC: 10279693.
DOI: 10.1038/s41389-023-00477-z.
Metastasis in neuroblastoma: the question.
Bhavsar S
Front Oncol. 2023; 13:1196861.
PMID: 37274289
PMC: 10233040.
DOI: 10.3389/fonc.2023.1196861.
Lipid Metabolic Reprogramming in Embryonal Neoplasms with MYCN Amplification.
Talapatra J, Reddy M
Cancers (Basel). 2023; 15(7).
PMID: 37046804
PMC: 10093342.
DOI: 10.3390/cancers15072144.
GSK2801 Reverses Paclitaxel Resistance in Anaplastic Thyroid Cancer Cell Lines through MYCN Downregulation.
Molteni E, Baldan F, Damante G, Allegri L
Int J Mol Sci. 2023; 24(6).
PMID: 36983070
PMC: 10054879.
DOI: 10.3390/ijms24065993.
Evaluating the RIST Molecular-Targeted Regimen in a Three-Dimensional Neuroblastoma Spheroid Cell Culture Model.
Kaess C, Matthes M, Gross J, Waetzig R, Heise T, Corbacioglu S
Cancers (Basel). 2023; 15(6).
PMID: 36980635
PMC: 10046822.
DOI: 10.3390/cancers15061749.
A novel MYCN-YTHDF1 cascade contributes to retinoblastoma tumor growth by eliciting mA -dependent activation of multiple oncogenes.
Luo Y, He M, Yang J, Zhang F, Chen J, Wen X
Sci China Life Sci. 2023; 66(9):2138-2151.
PMID: 36949231
DOI: 10.1007/s11427-022-2288-4.
GINS2 Promotes Osteosarcoma Tumorigenesis via STAT3/MYC Axis.
Ren B, Zheng Y, Nie L, Wu F, Huang L, Wei J
J Oncol. 2023; 2023:8454142.
PMID: 36873736
PMC: 9981285.
DOI: 10.1155/2023/8454142.
A Review of the Regulatory Mechanisms of N-Myc on Cell Cycle.
Li H, Dong L, Jin M, Li Q, Wang X, Jia M
Molecules. 2023; 28(3).
PMID: 36770809
PMC: 9920120.
DOI: 10.3390/molecules28031141.
Antigene Silencing by BGA002 Inhibits SCLC Progression Blocking mTOR Pathway and Overcomes Multidrug Resistance.
Bortolotti S, Angelucci S, Montemurro L, Bartolucci D, Raieli S, Lampis S
Cancers (Basel). 2023; 15(3).
PMID: 36765949
PMC: 9913109.
DOI: 10.3390/cancers15030990.